As of September 30, 2025, the Company had $104.0 million of cash, cash equivalents, and investment on hand. Since the end of the third quarter ended September 30, 2025, the Company raised a total of $73.8 million in net proceeds from the issuance of 4,976,510 shares of common stock from an underwritten public offering and ATM sales. The Company believes it has sufficient cash to fund operations into 2028 based on current operating plans and assumptions regarding clinical timelines and planned expenditures.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals reports Q3 EPS ($1.90), consensus ($1.71)
- CRBP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Corbus Pharmaceuticals management to meet virtually with B. Riley
- Corbus Pharmaceuticals Announces $70.5M Public Offering
- Corbus Pharmaceuticals 4.744M share Spot Secondary priced at $13.00